Skip to main content
1723 results

APSTJ 2024

https://www.certara.com/conference/apstj-2024/

Why are Clinical Data Standards Essential for EDC and Non-EDC Data? 

When you think of clinical data standardization, you might think of forms and datasets, or of CDISC’s CDASH, SDTM and ADaM models. And while these are an excellent and necessary starting point for standardization, it’s important to understand the many other ways you can use standardization to improve the efficiency of your clinical trials.    Clinical … Continued

https://www.certara.com/blog/why-are-clinical-data-standards-essential-for-edc-and-non-edc-data/

ISSX Workshop on Quantitative LC-MS/MS Proteomics

Location: Certara UK OfficesLevel 2-Acero1 Concourse WaySheffieldUnited Kingdom Online registration is available until: 6/29/2024 The workshop is neither trying to provide a 101 course on LCMS proteomics nor attempts to focus on what is new in LC-MS proteomics techniques. Attendees need to have some background but not necessarily leading experts in the field.

https://www.certara.com/live-events/issx-workshop-on-quantitative-lc-ms-ms-proteomics/

Certara Regulatory Workshop in Korea

On-site Workshop Overview Regulatory approval procedures are becoming increasingly stringent and time-consuming. Not having the right regulatory strategy in place will cost time and money, and may result in the failure or delay of your drug development program. It relayed to potential of Generative AI how it can help overcome those regulatory challenges.   The emergence … Continued

https://www.certara.com/live-events/certara-regulatory-workshop-in-korea/

Certara Announces Inaugural Client Conference with Keynote by Dr. Scott Gottlieb 

Agenda features discussion of life sciences industry trends, business value of model-informed drug development strategies, and impact of generative AI on biosimulation and regulatory sciences    RADNOR, PA– April. 18, 2024 – Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced that it will host the first-ever Certainty Conference. At this event, … Continued

https://www.certara.com/announcement/certara-announces-inaugural-client-conference-with-keynote-by-dr-scott-gottlieb/

The Challenges and Opportunities of Rare Disease Drug Development

New therapeutics development in rare diseases presents both opportunities and complexities. Because of the small patient pool available in these indications, there are challenges in designing and conducting clinical trials and the data interpretation that follows, and the ultimate path to registration. The top 3 critical downfalls in rare diseases development include Poor understanding of … Continued

https://www.certara.com/white-paper/the-challenges-and-opportunities-of-rare-disease-drug-development/

Pinnacle 21 demo

Build Validated Studies Up To 85% Faster: With Pinnacle 21 See how to achieve faster drug development, with less effort, and less manual work. The Pinnacle 21 software suite augments your capabilities – helping you quickly build validated studies, get cleaner vendor data (minus the delays), automate SDTM, and speed time-to-analysis. Powered by technology, you’ll … Continued

https://www.certara.com/pinnacle-21-enterprise-software/demo/
1 of 173